NeuroSigma.png
NeuroSigma Announces Commercial Launch of The Monarch eTNS® System for the Treatment of Pediatric ADHD at Annual Meeting of the American Academy of Child and Adolescent Psychiatry
October 17, 2022 09:00 ET | NeuroSigma, Inc.
LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced the commercial launch of The Monarch eTNS System at the annual meeting of...
NeuroSigma.png
NeuroSigma Announces Receipt of Permanent HCPCS Codes from CMS for Monarch eTNS System
September 27, 2022 12:00 ET | NeuroSigma, Inc.
LOS ANGELES, Sept. 27, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced that the Centers for Medicare & Medicaid Services ("CMS") has confirmed...
CMC logo.png
NeuroSigma Receives Bridge Financing from Checkmate Capital
September 21, 2020 11:00 ET | Checkmate Capital
To Support Targeted Commercialization and Global Partnering of FDA-Approved Non-Drug Treatment for Pediatric ADHD LOS ANGELES, Sept. 21, 2020 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. (“NeuroSigma”),...